<?xml version='1.0' encoding='utf-8'?>
<document id="28880240"><sentence text="Effect of Sipjeondaebo-Tang on the Pharmacokinetics of S-1, an Anticancer Agent, in Rats Evaluated by Population Pharmacokinetic Modeling." /><sentence text="S-1 (TS-1Â®) is an oral fluoropyrimidine anticancer agent containing tegafur, oteracil, and gimeracil"><entity charOffset="23-39" id="DDI-PubMed.28880240.s2.e0" text="fluoropyrimidine" /><entity charOffset="68-75" id="DDI-PubMed.28880240.s2.e1" text="tegafur" /><entity charOffset="77-85" id="DDI-PubMed.28880240.s2.e2" text="oteracil" /><entity charOffset="91-100" id="DDI-PubMed.28880240.s2.e3" text="gimeracil" /><pair ddi="false" e1="DDI-PubMed.28880240.s2.e0" e2="DDI-PubMed.28880240.s2.e0" /><pair ddi="false" e1="DDI-PubMed.28880240.s2.e0" e2="DDI-PubMed.28880240.s2.e1" /><pair ddi="false" e1="DDI-PubMed.28880240.s2.e0" e2="DDI-PubMed.28880240.s2.e2" /><pair ddi="false" e1="DDI-PubMed.28880240.s2.e0" e2="DDI-PubMed.28880240.s2.e3" /><pair ddi="false" e1="DDI-PubMed.28880240.s2.e1" e2="DDI-PubMed.28880240.s2.e1" /><pair ddi="false" e1="DDI-PubMed.28880240.s2.e1" e2="DDI-PubMed.28880240.s2.e2" /><pair ddi="false" e1="DDI-PubMed.28880240.s2.e1" e2="DDI-PubMed.28880240.s2.e3" /><pair ddi="false" e1="DDI-PubMed.28880240.s2.e2" e2="DDI-PubMed.28880240.s2.e2" /><pair ddi="false" e1="DDI-PubMed.28880240.s2.e2" e2="DDI-PubMed.28880240.s2.e3" /></sentence><sentence text=" Sipjeondaebo-tang (SDT) is a traditional oriental herbal medicine that has potential to alleviate chemotherapy-related adverse effects" /><sentence text=" The aim of the present study was to evaluate the effect of SDT on the pharmacokinetics of S-1" /><sentence text=" Sprague-Dawley rats were pretreated with a single dose or repeated doses of SDT for seven consecutive days (1200 mg/kg/day)" /><sentence text=" After the completion of pretreatment with SDT, S-1 was orally administered and plasma concentrations of tegafur, its active metabolite 5-FU, and gimeracil were determined by liquid chromatography-tandem mass spectrometry (LC/MS/MS)"><entity charOffset="105-112" id="DDI-PubMed.28880240.s6.e0" text="tegafur" /><entity charOffset="136-140" id="DDI-PubMed.28880240.s6.e1" text="5-FU" /><entity charOffset="146-155" id="DDI-PubMed.28880240.s6.e2" text="gimeracil" /><pair ddi="false" e1="DDI-PubMed.28880240.s6.e0" e2="DDI-PubMed.28880240.s6.e0" /><pair ddi="false" e1="DDI-PubMed.28880240.s6.e0" e2="DDI-PubMed.28880240.s6.e1" /><pair ddi="false" e1="DDI-PubMed.28880240.s6.e0" e2="DDI-PubMed.28880240.s6.e2" /><pair ddi="false" e1="DDI-PubMed.28880240.s6.e1" e2="DDI-PubMed.28880240.s6.e1" /><pair ddi="false" e1="DDI-PubMed.28880240.s6.e1" e2="DDI-PubMed.28880240.s6.e2" /></sentence><sentence text=" A population pharmacokinetic model was developed to evaluate the effect of SDT on pharmacokinetics of tegafur and 5-FU"><entity charOffset="103-110" id="DDI-PubMed.28880240.s7.e0" text="tegafur" /><entity charOffset="115-119" id="DDI-PubMed.28880240.s7.e1" text="5-FU" /><pair ddi="false" e1="DDI-PubMed.28880240.s7.e0" e2="DDI-PubMed.28880240.s7.e0" /><pair ddi="false" e1="DDI-PubMed.28880240.s7.e0" e2="DDI-PubMed.28880240.s7.e1" /></sentence><sentence text=" Although a single dose of SDT did not have any significant effect, the absorption rate of tegafur decreased, and the plasma levels of 5-FU reduced significantly in rats pretreated with SDT for seven days in parallel to the decreased gimeracil concentrations"><entity charOffset="91-98" id="DDI-PubMed.28880240.s8.e0" text="tegafur" /><entity charOffset="135-139" id="DDI-PubMed.28880240.s8.e1" text="5-FU" /><entity charOffset="234-243" id="DDI-PubMed.28880240.s8.e2" text="gimeracil" /><pair ddi="false" e1="DDI-PubMed.28880240.s8.e0" e2="DDI-PubMed.28880240.s8.e0" /><pair ddi="false" e1="DDI-PubMed.28880240.s8.e0" e2="DDI-PubMed.28880240.s8.e1" /><pair ddi="false" e1="DDI-PubMed.28880240.s8.e0" e2="DDI-PubMed.28880240.s8.e2" /><pair ddi="false" e1="DDI-PubMed.28880240.s8.e1" e2="DDI-PubMed.28880240.s8.e1" /><pair ddi="false" e1="DDI-PubMed.28880240.s8.e1" e2="DDI-PubMed.28880240.s8.e2" /></sentence><sentence text=" Population pharmacokinetic modeling also showed the enhanced elimination of 5-FU in the SDT-pretreated group"><entity charOffset="77-81" id="DDI-PubMed.28880240.s9.e0" text="5-FU" /></sentence><sentence text=" Repeated doses of SDT may inhibit the absorption of gimeracil, an inhibitor of 5-FU metabolism, resulting in enhanced elimination of 5-FU and decrease its plasma level"><entity charOffset="53-62" id="DDI-PubMed.28880240.s10.e0" text="gimeracil" /><entity charOffset="80-84" id="DDI-PubMed.28880240.s10.e1" text="5-FU" /><entity charOffset="134-138" id="DDI-PubMed.28880240.s10.e2" text="5-FU" /><pair ddi="false" e1="DDI-PubMed.28880240.s10.e0" e2="DDI-PubMed.28880240.s10.e0" /><pair ddi="false" e1="DDI-PubMed.28880240.s10.e0" e2="DDI-PubMed.28880240.s10.e1" /><pair ddi="false" e1="DDI-PubMed.28880240.s10.e0" e2="DDI-PubMed.28880240.s10.e2" /><pair ddi="false" e1="DDI-PubMed.28880240.s10.e1" e2="DDI-PubMed.28880240.s10.e1" /><pair ddi="false" e1="DDI-PubMed.28880240.s10.e1" e2="DDI-PubMed.28880240.s10.e2" /></sentence><sentence text="" /></document>